ClinicalTrials.gg
CompletedNCT02603705Updated Mar 5, 2018

Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain

A Phase 3 interventional study of Oxycodone extended-release in Moderate-to-severe Chronic Noncancer Pain, sponsored by Egalet Ltd. Completed at 39 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-03-05.

Sponsored by Egalet Ltd · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
281
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,283 studies in Chronic Pain with a site in United States — 258 open to participants now, 349 under way, 7 of them phase 3. Chronic Pain · United States.

Enrollment
136th of 1,092
281 · median 60
Started
2016
with 45 others
Phase 3
65 of 1,283
3 open now
Registered
302nd of 1,283
by date

Among the 1,283 studies in Chronic Pain with a site in United States, this one is the 136th largest by enrollment of the 1,092 interventional ones that give a count, is one of 46 that started in 2016, is one of 65 in phase 3, and was the 302nd registered.

Chronic Pain

3,228 studies on the registry are indexed under Chronic Pain; 729 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

258 of the 1,283 studies in Chronic Pain with a site in United States are open now. Recruiting first, the newest first:

253 more — sign in →

All 258 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,283 studies in Chronic Pain with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and tolerability of Egalet-002 in opioid-experienced patients with moderate-to-severe chronic noncancer pain.

03

Conditions studied

  • Moderate-to-severe Chronic Noncancer Pain

Browse trials for

Keywords

  • chronic pain
  • opioid
  • oxycodone
  • non cancer pain
  • moderate to severe
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is a man or woman between 18 and 75 years of age.
  • Has a clinical history of moderate-to-severe chronic noncancer pain ≥6 months.
  • Has required opioid therapy for at least 14 days prior to Screening at a dose between 20 mg and 160 mg (inclusive) oxycodone/day (or opioid equivalent), and will, in the opinion of the investigator, continue to require opioid therapy (between 20 mg and 240 mg oxycodone/day, inclusive) for management of moderate-to-severe pain for the duration of the study.
  • Has pain either not adequately controlled on current opioid regimen, requires a change of opioid due to tolerability of current opioid regimen or in the opinion of the investigator, would benefit from changing opioid for another reason.
  • Has stable health, as determined by the investigator.
  • If female, the patient is currently not pregnant, not breast-feeding, nor attempting to become pregnant (for 30 days before screening through the duration of the study), or is of non-.
  • Other Criteria Apply

Exclusion criteria

Exclusion Criteria:

  • Has cancer-related pain.
  • Is receiving >240 mg oxycodone daily (or opioid equivalent) within 30 days before Screening.
  • Has a history of attempted suicide.
  • Has used a spinal infusion pump within 6 months before Screening.
  • Has clinically unstable cardiac disease (including atrial fibrillation, symptomatic bradycardia, unstable congestive heart failure, or active myocardial ischemia) and/or respiratory disease (including or sleep apnea).
  • Has positive urine toxicity screen for drugs of abuse (with the exception of prescribed medications).
  • Has positive result for tetrahydrocannabinol (even if legally prescribed).
  • Has current (or history of within the last 12 months) drug dependence or substance abuse disorder according to , 5th Edition, Text Revision criteria (excluding nicotine).
  • Other Criteria Apply
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
281 participants (actual)

Study arms

  • Experimental
    Oxycodone extended-release

    Egalet abuse-deterrent, extended-release oxycodone tablet

    Drug: Oxycodone extended-release

06

What researchers measure

Primary outcomes

  1. Incidence of TEAEs during the Open-label Treatment Period, including those leading to treatment withdrawal, and/or abnormal physical examination findings, vital signs measurements, ECGs, and clinical laboratory test results, related to treatment

    Time frame: 1 year

Secondary outcomes

  1. Findings of the Brief Pain Inventory-Short Form (BPI-SF) during the Open-label Treatment Period

    Time frame: 1 year

07

Study locations

39 sites
  • Site 334
    Huntsville, Alabama 35801, United States
  • Site 328
    Tucson, Arizona 85712, United States
  • Site 332
    Jacksonville, Florida 32257, United States
  • Site 340
    Miami Gardens, Florida 33169, United States
  • Site 320
    Plantation, Florida 33317, United States
  • Site 302
    Tampa, Florida 33603, United States
  • Site 315
    Tampa, Florida 33613, United States
  • Site 310
    Winter Haven, Florida 33880, United States
  • Site 316
    Dawsonville, Georgia 30534, United States
  • Site 311
    Marietta, Georgia 30060, United States
  • Site 336
    Bloomington, Illinois 61701, United States
  • Site 345
    Blue Island, Illinois 60406, United States
  • Site 304
    Evansville, Indiana 47714, United States
  • Site 325
    Valparaiso, Indiana 46383, United States
  • Site 321
    Overland Park, Kansas 66210, United States
  • Site 342
    Wichita, Kansas 67205, United States
  • Site 329
    New Orleans, Louisiana 70114, United States
  • Site 326
    Quincy, Massachusetts 02169, United States
  • Site 303
    Saint Louis, Missouri 63141, United States
  • Site 306
    Las Vegas, Nevada 89119, United States
  • Site 313
    Belvidere, New Jersey 07823, United States
  • Site 346
    Blackwood, New Jersey 08012, United States
  • Site 323
    Hartsdale, New York 10530, United States
  • Site 338
    Mooresville, North Carolina 28117, United States
  • Site 333
    Cincinnati, Ohio 45212, United States
  • Site 343
    Cleveland, Ohio 44122, United States
  • Site 308
    Huber Heights, Ohio 45424, United States
  • Site 347
    Kettering, Ohio 45429, United States
  • Site 335
    Oklahoma City, Oklahoma 73112, United States
  • Site 312
    Eugene, Oregon 97401, United States
  • Site 322
    Duncansville, Pennsylvania 16635, United States
  • Site 324
    Wyomissing, Pennsylvania 19610, United States
  • Site 344
    Myrtle Beach, South Carolina 29588, United States
  • Site 314
    Summerville, South Carolina 29485, United States
  • Site 341
    New Tazewell, Tennessee 37825, United States
  • Site 318
    Austin, Texas 78731, United States
  • Site 330
    Dallas, Texas 75231, United States
  • Site 309
    San Antonio, Texas 78218, United States
  • Site 331
    West Jordan, Utah 84088, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Jun 2017, 15 months.

Of 49 phase 3 interventional studies under Chronic Pain, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2015
First posted
Nov 13, 2015
StartActual
Mar 7, 2016
Primary completionActual
Jun 15, 2017
CompletionActual
Jun 15, 2017
Last update
Mar 5, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02603705
Lead sponsor
Egalet Ltd
Responsible party
Sponsor
First posted
Nov 13, 2015
Start date
Mar 7, 2016
Primary completion
Jun 15, 2017
Completion
Jun 15, 2017
Last update
Mar 5, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxycodone

Start the discussion